Evaluation of TReatment With Angiotensin Converting Enzyme Inhibitors and the Risk of Lung Cancer: ERACER—An Observational Cohort Study
Author:
Affiliation:
1. Intermountain Heart Institute, Intermountain Medical Center, Salt Lake City, UT, USA
2. School of Medicine, University of Utah, Salt Lake City, UT, USA
3. School of Medicine, Stanford University, Stanford, CA, USA
Abstract
Publisher
SAGE Publications
Subject
Pharmacology (medical),Cardiology and Cardiovascular Medicine,Pharmacology
Link
http://journals.sagepub.com/doi/pdf/10.1177/1074248420987054
Reference29 articles.
1. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults
2. Antihypertensive therapy prescribing patterns and correlates of blood pressure control among hypertensive patients with chronic kidney disease
3. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
4. Health Outcomes Associated With Various Antihypertensive Therapies Used as First-Line Agents
5. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Dipeptidyl peptidase 4 (DPP-4) inhibitors and the risk of lung cancer: current evidence and future directions;Expert Review of Clinical Pharmacology;2022-12-28
2. Association between angiotensin-converting enzyme inhibitors and the risk of lung cancer: a systematic review and meta-analysis;British Journal of Cancer;2022-11-17
3. Cancer in patients with heart failure: Incidence, risk factors and prognostic impact;European Journal of Internal Medicine;2022-11
4. Modest Association of Long-Term ACE Inhibitor Treatment With Lung Cancer: The Promise and Pitfalls of Epidemiological Drug-Safety Analyses;Journal of Cardiovascular Pharmacology and Therapeutics;2021-03-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3